Lexaria Bioscience (NASDAQ: LEXX), developers of the revolutionary DehydraTECH(TM) drug-delivery technology, has released study results focused on THC-A21-1, a THC oral format. According to the announcement, the study showed that Lexaria’s DehydraTECH THC solution delivers THC levels to blood plasma an estimated three times faster than standard MCT-based THC. Based on study results, it took only 15 minutes using oral ingestion of the substance to reach THC levels comparable to those reached in 45 minutes using “coconut-oil” formulations. As the THC left the system at the six-hour mark, levels were comparable and demonstrated the fast-on, fast-off performance. The DehydraTECH results are timely because the House Judiciary Committee last week passed the MORE Act, which signifies a general movement toward federal legalization of the drug. While the LEXX study was focused on the potential of advancing DehydraTECH THC as a medicinal solution, the results can be applied to a larger market. “THC consumers today include . . . medicinal and pharmaceutical users,” said Lexaria BioScience CEO Chris Bunka in the press release. “Our objective is to provide them rapid onset and high bioavailability without harmful delivery mechanisms like smoking.”
To view the full press release, visit https://ibn.fm/fRx0A
About Lexaria Bioscience Corp.
Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption of cannabinoids and nicotine by 5 to 10 times, and, in some instances with cannabinoids by as much as 27 times, compared to standard industry formulations, as well as reduce time of onset from one to two hours to minutes, and mask unwanted tastes. The delivery systems are also being evaluated for orally administered, anti-viral drugs, nonsteroidal, anti-inflammatory drugs (NSAIDs) and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and more than 50 patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.